Navigation Links
Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
Date:10/7/2008

mmatory bowel disease [IBD], ophthalmology and cystic fibrosis) and also offer insights into potentially new pharmaceutical applications.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known, but previously elusive anti-inflammatory drug target. At the same time, they also protect cells and tissues against inflammatory damage. Morria is determined to become a pivotal player in the $20 billion anti-inflammatory drug market by developing and commercializing novel drugs for acute pulmonary and gastro-intestinal inflammatory diseases. For more information, please visit http://www.morria.com .

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.

Contacts:

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer, Investors

cheer@rlcinc.com

Timothy Rathschmidt, Media

trathschmidt@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
2. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
3. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
4. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
8. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
9. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... September 18, 2014 OMICS Group ... globe to participate in the ‘Open Access Week’ ... to OMICS Group Pharma Journals from ... of the fastest emerging Sciences, accelerating with a ... services across the globe. The industry is gearing ...
(Date:9/18/2014)... pretty expensive. Now a team led by an engineer ... of designs that will let scientists slash the cost ... pump. , Syringe pumps are used to dispatch precise ... chemicals in a reaction. They can also cost hundreds ... his team of Michigan Tech students published the library ...
(Date:9/18/2014)... Just about everything we touch in the course ... detergent - even medicines, rely on the chemical ... by-products, minerals and farm products into valuable chemicals ... , QUT scientist Dr Sarina Sarina, who achieved ... production process at ambient temperature using light instead ...
Breaking Biology Technology:Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Doing science just got cheaper -- and faster 2Using solar energy to turn raw materials into ingredients for every day life 2
... BioLife,s Proprietary, Next Generation, Biopreservation, Media Resulted in Increased Yield ... ... Cells, BOTHELL, Wash., Oct. 24 ... of,proprietary hypothermic storage and cryopreservation media products for,cells, tissues, and organs, ...
... Corp. (Other,OTC: IDTA.PK) released today the Jant Pharmacal ... and Oversees markets., - The strategic partnership ... continues, has resulted in increasing market,penetration over the ... sales,have increased significantly in the United States with ...
... Notice of Allowance of European Patent Application Covering Its Core ... Product Applications Protection Rights to All Cytokine ... ... GenOdyssee (GO), a biotechnology,company dedicated to the discovery and development of ...
Cached Biology Technology:BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 2BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 3BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 4International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 2GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 3GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 4
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... (MGH) researchers have developed a new type of miniature ... expand the application of minimally invasive diagnostic and therapeutic ... the team from the Wellman Center for Photomedicine at ... its use in a mouse model. , ...
... 4 cases of botulism following cosmetic injections to the ... unlicensed preparation that resulted in toxin levels up to ... a report in the November 22/29 issue of JAMA. ... by the toxins of the spore-forming bacterium Clostridium botulinum ...
... collaborating institutions report in this week's Science a ... 2.8 kilometers below Earth's surface. Think that's weird? ... water molecules to useable energy. , The ... the three-dimensional shell that encompasses all planetary life. ...
Cached Biology News:Three-dimensional, miniature endoscope opens new diagnostic possibilities 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 3Bacteria that use radiated water as food 2Bacteria that use radiated water as food 3
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Shaker combines shaking and rocking for maximal fluid ... 330 mm stainless steel or acrylic platform, it ... room operation. The platform angle is easily adjusted ... with action and rotation speed of platform is ...
...
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
Biology Products: